A Study to Examine the Safety and Tolerability of MK0517 for the Prevention of Post-Operative Nausea and Vomiting (0517-015)(COMPLETED)

• Number of Patients With Clinical Adverse Experiences (CAEs) [ Time Frame: Baseline and 24 hours ] [ Designated as safety issue: Yes ]
  An adverse experience (AE) is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product
• Number of Patients With Laboratory Adverse Experiences (LAEs) [ Time Frame: Baseline and 24 hours ] [ Designated as safety issue: Yes ]
  A laboratory adverse experience (LAE) is defined as any unfavorable and unintended change in the chemistry of the body temporally associated with the use of the SPONSOR'S product, whether or not considered related to the use of the product.

• Number of Patients With Drug-related CAEs [ Time Frame: Baseline and 24 hours ] [ Designated as safety issue: Yes ]
  Patients with drug-related (as assessed by an investigator who is a qualified physician according to his/her best clinical judgment) CAEs
• Number of Patients With Serious CAEs [ Time Frame: Baseline and 24 hours ] [ Designated as safety issue: Yes ]
  Serious CAEs are any AEs occurring at any dose that; Results in death; or Is life threatening; or Results in a persistent or significant disability/incapacity; or Results in or prolongs an existing inpatient hospitalization; or Is a congenital anomaly/birth defect; or Is a cancer; or Is an overdose

A new intravenous medication is being tested for the prevention of the nausea and vomiting that occurs after surgery. This new medication is being compared to another intravenous medication that is already available to patients for this indication.

• Drug: Comparator: MK0517
  a single administration of 40 mg MK0517 by IV immediately prior to surgery
• Drug: Comparator: ondansetron
  a single administration of 4 mg ondansetron by IV immediately prior to surgery
  Other Name: Zofran

• Experimental: 1
  40 mg MK0517 IV
  Intervention: Drug: Comparator: MK0517
• Active Comparator: 2
  4 mg ondansetron IV
  Intervention: Drug: Comparator: ondansetron

Inclusion Criteria:

• Open abdominal surgery requiring 24 hour hospital stay
• General anesthesia
• Post-operative opioids
• ASA status of I-III

Exclusion Criteria:

• Patient exhibits evidence of any clinically significant respiratory, metabolic, hepatic, renal dysfunction, or cardiovascular condition or congestive heart failure (CHF)
• Morbid obesity
• Patient is mentally incapacitated or has a significant emotional or psychiatric disorder